Tezepelumab by Amgen for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
Tezepelumab is under clinical development by Amgen and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD).
Tezepelumab is under clinical development by Amgen and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD).